IMPORTANT: Copyright disclaimer:This material is presented to ensure timely dissemination of scholarly and technical work. Copyright and all rights therein are retained by authors or by other copyright holders. All persons copying this information are expected to adhere to the terms and constraints invoked by each author's copyright. In most cases, these works may not be reposted without the explicit permission of the copyright holder.



  • Gene expression-guided selection of histopathology image features. E. Budinska, L.Capkova, D. Schwarz, L. Dusek, R. Jaggi, J. Feit, V. Popovici. 15th IEEE Conf. on Bioinformatics and Bioengineering (BIBE). Belgrade, Nov. 2-4, 2015. DOI: 10.13140/RG.2.1.1765.5760 
  • Hierarchical contexts from breast cancer histopathology images. V. Popovici, R. Jaggi, J. Feit. 4th Intl. Conf. on Computational and Mathematical Biomedical Engineering (CMBE).  Paris June 29 - July 1, 2015.DOI:  10.13140/RG.2.1.2552.6881 
  • MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients. Van Schaeybroeck,  et al. Journal of Clinical Oncology. 33(15).


  • Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. E Missiaglia, B Jacobs, G D'Ario, AF Di Narzo, C Soneson, E Budinska, V Popovici, L Vecchione, S Gerster, P Yan, AD Roth, D Klingbiel, FT Bosman, M Delorenzi, S Tejpar. Annals of Oncology. 2014.
  • Test of Four Colon Cancer Risk-Scores in Formalin Fixed Paraffin Embedded Microarray Gene Expression Data. A.F. Di Narzo, S. Tejpar, S. Rossi, P. Yan, V. Popovici, P. Wirapati, E. Budinska, T. Xie, H. Estrella, A. Pavlicek, M. Mao, E. Martin, W. Scott, F. Bosman, A. Roth, M. Delorenzi. Journal of National Cancer Institute. 2014. 106(10)


  • Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer. V. Popovici, E. Budinska, F. Bosman, S. Tejpar, A. Roth, M. Delorenzi. BMC Cancer. 2013. 13(1):439
  • Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. E. Budinska, V. Popovici, S. Tejpar, G. D'Ario, N. Lapique, K.O. Sikora, A.F. Di Narzo, P. Yan, J.G. Hodgson, S. Weinrich, F. Bosman, A. Roth, M. Delorenzi. Journal of Pathology. 2013. 231(1):63-76
  • BRAF and KRAS mutations as additional risk factors in the context of clinical parameters of patients with colorectal cancer. V. Popovici, E. Budinská, A. Roth, F. Bosman, S. Tejpar, M. Delorenzi. ASCO Annual Meeting 2013
  • Colorectal cancer heterogeneity from a gene expression perspective.  E. Budinská, A. Janotová, V. Popovici, G. D’Ario, N. Lapique, S.K. Otylia, A.F., Di Narzo, Y. Pu, H.J. Graeme, S. Weinrich, F. Bosman, A. Roth, M. Delorenzi. ASCO Annual Meeting 2013
  • Connecting gene expression subtypes of colorectal cancer (CRC) with cell lines and drug resistance.  E. Budinska, J. Wilding, V. Popovici, E. Missiaglia, A. Roth, F. Bosman, M. Delorenzi, W. Bodmer, S. Tejpar. ASCO Annual Meeting 2013
  • Identification of synthetic lethal interactions with the BRAF oncogene in colorectal cancer. L. Vecchione, V. Gambino, G. d'Ario, T. Sun, I. Simon, V. Popovici, M. Delorenzi, R.  Bernards, S. Tejpar. AACR Annual Meeting 2013
  • The EurOPDX consortium: Sharing patient tumor-derived xenografts for collaborative multicentric preclinical trials. E. Vinolo, E. Marangoni, V. Serra, F. Amant, A. Bertotti, A. V Biankin, A-L Børresen-Dale, A. Bruna, E.Budinská, A. Byrne, C. Caldas, D. Chang, R. Clarke, E. Hermans, M. Hidalgo, S. de Jong, J. Jonkers, P. López, G.M. Mælandsmo, V. Popovici, S. Roman-Roman, J. Seoane, L. Trusolino, A. Villanueva. AACR Annual Meeting 2013


  • A robust genomic signature for detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency. T. Sun, P. Roepman, V. Popovici, M. Michaut, I. Majewski, R. Salazar, C. Santos, R. Rosenberg, U. Nitsche, W.E. Mesker, S. Bruin, S. Tejpar, M. Delorenzi, R. Bernards, I. Simon. Journal of Pathology, 228(4), 586-595, 2012, PMID: 22926706
  • A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations. T. Xie, G. D' Ario, JR Lamb, E. Martin, K. Wang, S. Tejpar, M. Delorenzi, F. Bosman, A. Roth, P. Yan, S. Bougel, AF Di Narzo, V. Popovici, E. Budinska, M. Mao, SL Weinrich, PA Rejto, HG Hodgson. PLoS One, 2012;7(7):e42001. Epub 2012 Jul 31. PMID: 22860045
  • Identification of a Poor-Prognosis BRAF-Mutant–Like Population of Patients With Colon Cancer. V. Popovici,  E. Budinska, S. Tejpar, S. Weinrich, H. Estrella, G. Hodgson, E. Van Cutsem, T. Xie, F.T. Bosman, A.D. Roth, M. Delorenzi. Journal of Clinical Oncology, 30(12):1288-1295, 2012, PMID: 22393095
  • Molecular and clinicopathologic evidence of heterogeneity in KRAS-mutant colon cancers. V. Popovici, E. Budinska, S. Tejpar, G. d'Ario, A.F. Di Narzo, J.G. Hodgson, A. Roth, F. Bosman, M. Delorenzi. ASCO Annual Meeting 2012
  • Identification of the BRAF-like Signature Predictive of Response Towards MEK Inhibition by Pimasertib (MSC1936369B) in Colorectal Cancer Cell Lines. V. De Vriendt, K. Sikora, B. Van den Bosch, V. Popovici, M. Delorenzi, S. Tejpar. European Journal of Cancer 48 Supp.6 (2012): 134-135


  • Rgtsp: a generalized top scoring pairs package for class prediction. V. Popovici, E. Budinska, M. Delorenzi. Bioinformatics, 27(12):1729-1730, 2011, PMID: 21505033


  • The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. MAQC Consortium. Nature Biotechnology, vol. 28, no. 8, 2010, PMID: 20676074
  • Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. J. Antonov, V. Popovici, M. Delorenzi, P. Wirapati, A. Baltzer, A. Oberli, B. Thurlimann, A. Giobbie-Hurder, G. Viale, H.J. Altermatt, S. Aebi, R. Jaggi. BMC Cancer, vol. 10, article 37, February 2010, PMID: 20144231
  • Effect of training sample size and classification difficulty on the accuracy of genomic predictors. V. Popovici, W. Chen, B.G. Gallas, C. Hatzis, W. Shi, F.W. Samuelson, Y. Nikolsky, M. Tsyganova, A. Ishkin, T. Nikolskaya, K.R. Hess, V. Valero, D. Booser, M. Delorenzi, G.N. Hortobagyi, L. Shi, W.F. Symmans, L. Pusztai. Breast Cancer Research, 12(1):R5, January 2010, PMID: 20064235
  • Examination of FGFRL1 as a candidate gene for diaphragmatic defects at chromosome 4p16.3 shows that Fgfrl1-null mice have reduced expression of Tpm3, sarcomere genes and Lrtm1 in the diaphragm. N. Lopez-Jimenez, S. Gerber, V. Popovici, S. Mirza, K. Copren, L. Ta, G.M. Shaw, B. Trueb, A.M. Slavotinek. Human Genetics, 127(3):325-36 2010, PMID: 20024584